Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours
Arch Cardiovasc Dis. 2024 Apr 12:S1875-2136(24)00058-5. doi: 10.1016/j.acvd.2024.02.012. Online ahead of print.ABSTRACTAround 10% of patients with acute coronary syndrome are treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants for various indications. The initial management of these patients is highly complex, and new guidelines specify that, only during percutaneous coronary intervention, a bolus of unfractionated heparin is recommended in one of the following circumstances: (1) if the patient is receiving a non-vitamin K antagonist oral anticoagulant; or (2) if the international normalized ratio is<2.5 in a patient being treated with a vitamin K antagonist. In this review, we report on five key messages essential for the management of these patients. There are no randomized studies to date, and we propose two diagnostic and/or therapeutic decision algorithms. However, randomized studies are needed to validate these strategies.PMID:38644068 | DOI:10.1016/j.acvd.2024.02.012
Source: Archives of Cardiovascular Diseases - Category: Cardiology Authors: Alexandre Salaun Emmanuel de Maistre Marl ène Daller Chan Sombrun Fr édéric Chagué Florence Bichat Luc Rochette Nicolas Danchin Laurent Fauchier Marianne Zeller Yves Cottin Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Study | Vitamin K | Vitamins